Statements (95)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:software
gptkb:drug |
| gptkbp:activities |
HMG-Co A reductase inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:associated_with |
reduced cardiovascular events
|
| gptkbp:brand |
gptkb:rosuvastatin_calcium
gptkb:Crestor |
| gptkbp:class |
statins
|
| gptkbp:clinical_trial |
Phase III
hyperlipidemia JUPITER trial prevent cardiovascular disease reduced risk of cardiovascular death reduced risk of stroke primary prevention of cardiovascular disease reduced risk of myocardial infarction secondary prevention of cardiovascular disease |
| gptkbp:contraindication |
liver disease
pregnancy breastfeeding |
| gptkbp:cuisine |
weight management
regular check-ups smoking cessation diet and exercise alcohol moderation |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:dosage_form |
gptkb:tablet
5 mg tablet 10 mg tablet 20 mg tablet 40 mg tablet |
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:has_ability |
10 mg
5 mg 20 mg 40 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Crestor
|
| gptkbp:indication |
hyperlipidemia
|
| gptkbp:ingredients |
gptkb:rosuvastatin
|
| gptkbp:interacts_with |
gptkb:cyclosporine
gptkb:warfarin antacids other statins |
| gptkbp:invention |
gptkb:2016
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_monitored_by |
liver function tests
lipid levels |
| gptkbp:is_used_for |
lowering cholesterol
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:2003 gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe multiple countries |
| gptkbp:population |
adults
children over 10 years |
| gptkbp:previous_name |
gptkb:rosuvastatin_calcium
|
| gptkbp:requires |
gptkb:theorem
available online |
| gptkbp:research |
Crestor and cardiovascular outcomes
Crestor and drug interactions Crestor and exercise capacity Crestor and inflammation markers Crestor and liver enzymes Crestor and quality of life Crestor and renal function Crestor efficacy in diabetes Crestor in elderly patients Crestor long-term safety Crestor vs placebo |
| gptkbp:scholarships |
avoid alcohol
liver function tests recommended monitor for muscle symptoms dietary restrictions recommended |
| gptkbp:side_effect |
headache
muscle pain nausea abdominal pain allergic reactions constipation kidney damage gastrointestinal issues diabetes risk increase |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
active liver disease
high cholesterol guidelines unexplained persistent elevations of transaminases |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:bfsParent |
gptkb:Astra_Zeneca_Group
|
| gptkbp:bfsLayer |
5
|